Nctid:
NCT00001756
Payload:
{"hasResults"=>false, "derivedSection"=>{"miscInfoModule"=>{"versionHolder"=>"2024-10-21"}, "conditionBrowseModule"=>{"meshes"=>[{"id"=>"D000008415", "term"=>"Mastocytosis"}], "ancestors"=>[{"id"=>"D000009372", "term"=>"Neoplasms, Connective Tissue"}, {"id"=>"D000018204", "term"=>"Neoplasms, Connective and Soft Tissue"}, {"id"=>"D000009370", "term"=>"Neoplasms by Histologic Type"}, {"id"=>"D000009369", "term"=>"Neoplasms"}, {"id"=>"D000090362", "term"=>"Mast Cell Activation Disorders"}, {"id"=>"D000007154", "term"=>"Immune System Diseases"}], "browseLeaves"=>[{"id"=>"M11399", "name"=>"Mastocytosis", "asFound"=>"Mastocytosis", "relevance"=>"HIGH"}, {"id"=>"M24449", "name"=>"Mastocytosis, Systemic", "relevance"=>"LOW"}, {"id"=>"M12317", "name"=>"Neoplasms, Connective Tissue", "relevance"=>"LOW"}, {"id"=>"M20350", "name"=>"Neoplasms, Connective and Soft Tissue", "relevance"=>"LOW"}, {"id"=>"M12315", "name"=>"Neoplasms by Histologic Type", "relevance"=>"LOW"}, {"id"=>"M2776", "name"=>"Mast Cell Activation Disorders", "relevance"=>"LOW"}, {"id"=>"M10200", "name"=>"Immune System Diseases", "relevance"=>"LOW"}, {"id"=>"T3626", "name"=>"Mastocytosis", "asFound"=>"Mastocytosis", "relevance"=>"HIGH"}, {"id"=>"T5562", "name"=>"Systemic Mastocytosis", "relevance"=>"LOW"}], "browseBranches"=>[{"name"=>"Neoplasms", "abbrev"=>"BC04"}, {"name"=>"Immune System Diseases", "abbrev"=>"BC20"}, {"name"=>"All Conditions", "abbrev"=>"All"}, {"name"=>"Skin and Connective Tissue Diseases", "abbrev"=>"BC17"}, {"name"=>"Rare Diseases", "abbrev"=>"Rare"}]}}, "protocolSection"=>{"designModule"=>{"bioSpec"=>{"retention"=>"SAMPLES_WITHOUT_DNA", "description"=>"Whole Blood, Serum, White Cells"}, "studyType"=>"OBSERVATIONAL", "designInfo"=>{"timePerspective"=>"PROSPECTIVE", "observationalModel"=>"CASE_CONTROL"}, "enrollmentInfo"=>{"type"=>"ACTUAL", "count"=>202}}, "statusModule"=>{"overallStatus"=>"COMPLETED", "startDateStruct"=>{"date"=>"1997-12-03", "type"=>"ACTUAL"}, "expandedAccessInfo"=>{"hasExpandedAccess"=>false}, "statusVerifiedDate"=>"2022-11", "completionDateStruct"=>{"date"=>"2022-11-03", "type"=>"ACTUAL"}, "lastUpdateSubmitDate"=>"2022-11-04", "studyFirstSubmitDate"=>"1999-11-03", "studyFirstSubmitQcDate"=>"1999-11-03", "lastUpdatePostDateStruct"=>{"date"=>"2022-11-07", "type"=>"ACTUAL"}, "studyFirstPostDateStruct"=>{"date"=>"1999-11-04", "type"=>"ESTIMATED"}, "primaryCompletionDateStruct"=>{"date"=>"2021-11-01", "type"=>"ACTUAL"}}, "outcomesModule"=>{"primaryOutcomes"=>[{"measure"=>"Use of G-CSF administration healthy volunteers to mobilize and enhance CD34+ hematopoietic progenitor cell numbers into the peripheral blood in order to culture and characterize human mast cells, study and characterize CD34+ -derived human ma...", "timeFrame"=>"12/31/2029", "description"=>"Use of G-CSF administration healthy volunteers to mobilize and enhance CD34+ hematopoietic progenitor cell numbers into the peripheral blood in order to culture and characterize human mast cells, study and characterize CD34+ -derived human mast cells."}, {"measure"=>"Collection of CD34+ cells with or without use of Plerixafor administration in patients with systemic mastocytosis and other related allergic, hematological and immunological conditions to mobilize and enhance CD34+ cells into the peripheral b...", "timeFrame"=>"12/31/2029", "description"=>"Collection of CD34+ cells with or without use of Plerixafor administration in patients with systemic mastocytosis and other related allergic, hematological and immunological conditions to mobilize and enhance CD34+ cells into the peripheral blood to culture and learn how mast cells contribute to these disease states."}]}, "conditionsModule"=>{"keywords"=>["Leukapheresis", "Mastocytosis", "Mast Cells", "Normal Volunteer", "Natural History", "Systemic Mastocytosis"], "conditions"=>["Mastocytosis", "Healthy Volunteer"]}, "referencesModule"=>{"references"=>[{"pmid"=>"8334430", "type"=>"BACKGROUND", "citation"=>"Schwinger W, Mache C, Urban C, Beaufort F, Toglhofer W. Single dose of filgrastim (rhG-CSF) increases the number of hematopoietic progenitors in the peripheral blood of adult volunteers. Bone Marrow Transplant. 1993 Jun;11(6):489-92."}, {"pmid"=>"16799601", "type"=>"BACKGROUND", "citation"=>"Metcalfe DD. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol. 1991 Mar;96(3 Suppl):2S-4S; discussion 4S, 60S-65S. doi: 10.1111/1523-1747.ep12468882."}, {"pmid"=>"35251038", "type"=>"DERIVED", "citation"=>"Falduto GH, Pfeiffer A, Zhang Q, Yin Y, Metcalfe DD, Olivera A. A Critical Function for the Transcription Factors GLI1 and GLI2 in the Proliferation and Survival of Human Mast Cells. Front Immunol. 2022 Feb 16;13:841045. doi: 10.3389/fimmu.2022.841045. eCollection 2022."}, {"pmid"=>"21134978", "type"=>"DERIVED", "citation"=>"Wilson TM, Maric I, Simakova O, Bai Y, Chan EC, Olivares N, Carter M, Maric D, Robyn J, Metcalfe DD. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica. 2011 Mar;96(3):459-63. doi: 10.3324/haematol.2010.031690. Epub 2010 Dec 6."}, {"pmid"=>"20004787", "type"=>"DERIVED", "citation"=>"Prussin C, Lee J, Foster B. Eosinophilic gastrointestinal disease and peanut allergy are alternatively associated with IL-5+ and IL-5(-) T(H)2 responses. J Allergy Clin Immunol. 2009 Dec;124(6):1326-32.e6. doi: 10.1016/j.jaci.2009.09.048."}], "seeAlsoLinks"=>[{"url"=>"https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_1998-I-0027.html", "label"=>"NIH Clinical Center Detailed Web Page"}]}, "descriptionModule"=>{"briefSummary"=>"This study will investigate mast cell precursors that circulate in the blood. In a group of diseases collectively known as mastocytosis, mast cells accumulate in abnormal amounts in the skin, lymphoid tissues, bone marrow, liver and spleen. Some forms of mastocytosis have a generally good prognosis; for others, the prognosis is poorer. There is no known cure for any form of the disease. A better understanding of mast cells and how they respond to certain substances may provide insights that will lead to effective treatments for mastocytosis.\n\nPatients with systemic mastocytosis and normal healthy volunteers between the ages of 20 and 60 may be eligible for this 8-day study. Participants will undergo the following procedures:\n\n* Day 1 Medical history, physical examination, and blood tests to assess general health status\n* Days 2 through 6 Daily injections under the skin of G-CSF a hormone that stimulates white blood cell production\n* Day 7 Leukapheresis a procedure for collecting large numbers of white blood cells. In leukapheresis, blood is drawn through a needle placed in an arm and channeled into a cell separator machine. The white cells are collected and the rest of the blood is returned to the body through a needle in the other arm. The procedure takes up to 3 hours.\n* Days 7 and 8 Blood draw (about 1 teaspoon) to monitor white blood cell counts.", "detailedDescription"=>"The purpose of this protocol is to obtain large numbers of CD34+ cells from the peripheral blood of healthy volunteers and patients with systemic mastocytosis or other related allergic, hematological, and immunological conditions by leukapheresis for culture and characterization of mast cell progenitor cells and their response to various cytokines and anti-mitotic agents. Healthy volunteers and patients will be adults of both sexes from 18 to 70 years of age. Granulocyte colony stimulating factor (G-CSF) will be administered to healthy volunteers at dose of 10 mcg/kg/day as a subcutaneous dose daily for 5 days not to exceed 960mcg. Patients will receive Plerixafor at a dose of 0.24 mg/kg as a single subcutaneous dose not to exceed 24mg the night before leukapheresis as a mobilizing agent for CD34+ cells. In identified patients where leukapheresis yield is considered adequate without stimulation by the principal investigator, leukapheresis may proceed without stimulation. Healthy volunteers will undergo a single leukapheresis at day 7, and patients will undergo a single leukapheresis at day 3 or 4. This is not a therapeutic protocol and does not involve reinfusion of any manipulated cells, viruses or DNA constructs back into human subjects."}, "eligibilityModule"=>{"sex"=>"ALL", "stdAges"=>["ADULT", "OLDER_ADULT"], "maximumAge"=>"70 years", "minimumAge"=>"18 years", "samplingMethod"=>"NON_PROBABILITY_SAMPLE", "studyPopulation"=>"Primary Clinical", "healthyVolunteers"=>true, "eligibilityCriteria"=>"* SUBJECT INCLUSION CRITERIA:\n\nHealthy Volunteers must:\n\n1. Be 18-70 years of age\n2. Be healthy\n3. Have adequate peripheral venous access\n4. Have normal renal function (creatinine less than or equal to 1.5mg/dL; less than or equal to 1 plus proteinuria)\n5. Have normal hepatic function (bilirubin less than or equal to 1.5 mg/dL)\n6. Have normal hematologic function (WBC greater than or equal to 3000/mm(3); granulocytes greater than or equal to 1500/mm(3) ; platelets greater than or equal to 175,000; hemoglobin greater than or equal to 12.5 g/dL)\n\nPatients must:\n\n1. Be 18-70 years of age\n2. Have mast cell hyperplasia compatible with a diagnosis of systemic mastocytosis (applicable to systemic mastocytosis patients only) or other allergic, hematologic, or immunologic condition\n3. Have adequate peripheral venous access or be willing to have a central line placed.\n4. First be admitted as inpatients under an existing NIH protocol\n5. Have preserved renal function (creatinine less than or equal to 2 mg/dL; less than or equal to 2 plus proteinuria)\n6. Have preserved hepatic function (bilirubin less than or equal to 1.5 mg/dL)\n7. Have preserved hematologic function (WBC greater than or equal to 3000/mm(3); granulocytes greater than or equal to 1500/mm(3) ; platelets greater than or equal to 175,000; hemoglobin greater than or equal to 12.5 g/dL)\n\nAll female subjects of childbearing potential:\n\n1. May be enrolled if using effective contraception\n2. Have a negative serum or urine pregnancy test determined within 72 hours before beginning Plerixafor or G-CSF administration\n\nSUBJECT EXCLUSION CRITERIA:\n\nAll subjects must not meet any of the following criteria:\n\nHealthy Volunteers and patients must not:\n\n1. Have active bacterial, fungal or viral infections\n2. Have viral screens positive for HIV or hepatitis B or C\n3. Be pregnant or lactating\n4. Have a history of autoimmune disease such as rheumatoid arthritis, vasculitis, pyoderma gangrenosum or similar disorder\n5. Have any condition, which in the judgment of the investigator, might place the subject at undue risk\n\nHealthy Volunteers with any of the following will be excluded:\n\n1. Splenomegaly, pulmonary fibrosis and other related conditions\n2. Use of any investigative drugs within the past 12 months\n3. Have a significant coagulation disorder\n\nSystemic Mastocytosis and Mast Cell Related Condition Patients with any of the following will be excluded:\n\n1. Patients taking any other growth factors, cytokines or investigative drugs\n2. Patients who are hemodynamically unstable (blood pressure systolic of lower than 105 or diastolic lower than 65)"}, "identificationModule"=>{"nctId"=>"NCT00001756", "briefTitle"=>"Study of Mast Cell Precursors", "organization"=>{"class"=>"NIH", "fullName"=>"National Institutes of Health Clinical Center (CC)"}, "officialTitle"=>"The Characterization of CD34+ Derived Mast Cell Precursors", "orgStudyIdInfo"=>{"id"=>"980027"}, "secondaryIdInfos"=>[{"id"=>"98-I-0027"}]}, "armsInterventionsModule"=>{"armGroups"=>[{"label"=>"Healthy Volunteers", "description"=>"Healthy Volunteers"}, {"label"=>"Patients", "description"=>"Patients have mast cell hyperplasia compatible with a diagnosis of systemic mastocytosis (applicable to systemic mastocytosis patients only) or other allergic, hematologic, orimmunologic condition."}]}, "contactsLocationsModule"=>{"locations"=>[{"zip"=>"20892", "city"=>"Bethesda", "state"=>"Maryland", "country"=>"United States", "facility"=>"National Institutes of Health Clinical Center", "geoPoint"=>{"lat"=>38.98067, "lon"=>-77.10026}}], "overallOfficials"=>[{"name"=>"Melody C Carter, M.D.", "role"=>"PRINCIPAL_INVESTIGATOR", "affiliation"=>"National Institute of Allergy and Infectious Diseases (NIAID)"}]}, "sponsorCollaboratorsModule"=>{"leadSponsor"=>{"name"=>"National Institute of Allergy and Infectious Diseases (NIAID)", "class"=>"NIH"}, "responsibleParty"=>{"type"=>"SPONSOR"}}}}
